Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)

Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)

SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major…

Innovent Biologics and Ollin Bio Report Clinical Progress on Dual-Targeting VEGF/ANG-2 Antibody IBI324

Innovent Biologics, Inc. and its partner Ollin Bio anno […] The post Innovent Biologics and Ollin Bio Report Clinical Progress on Dual-Targeting VEGF/ANG-2 Antibody IBI324 first appeared on GeneOnline News. The post Innovent Biologics and Ollin Bio Report Clinical Progress on Dual-Targeting VEGF/ANG-2 Antibody IBI324 appeared first on GeneOnline News.

150+ Patient Trial: Innovent's Enhanced VEGF/Ang2 Drug Aims to Beat Market Leader in Eye Disease

Innovent and Ollin's IBI324 completes JADE trial enrollment for wAMD and DME treatment. Higher potency bispecific antibody shows promise vs faricimab. Topline results expected Q1 2026.

Innovent's Partner Ollin Announces Clinical Updates on ...